MIR377

Summary

MIR377 (microRNA 377, HGNC:31870) is a microRNA gene on chromosome 14q32.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 494326 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31870
Approved symbol	MIR377
Name	microRNA 377
Location	14q32.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-377
Ensembl gene	ENSG00000199015
Ensembl biotype	miRNA
Entrez	494326
RNAcentral	URS000075AF10 — miRNA, 69 nt, 26 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362145

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362145 — 1 exons

Exon	Start	End
ENSE00001436908	101062050	101062118

Expression profiles

Bgee: expression breadth broad, 69 present calls, max score 96.05.

Top tissues by expression

69 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	96.05	gold quality
kidney	UBERON:0002113	94.34	gold quality
placenta	UBERON:0001987	91.16	gold quality
blood	UBERON:0000178	88.97	gold quality
myometrium	UBERON:0001296	78.36	gold quality
islet of Langerhans	UBERON:0000006	77.79	gold quality
left coronary artery	UBERON:0001626	75.58	gold quality
adrenal gland	UBERON:0002369	75.56	gold quality
muscle of leg	UBERON:0001383	75.41	gold quality
calcaneal tendon	UBERON:0003701	74.99	gold quality
lung	UBERON:0002048	74.73	gold quality
stomach	UBERON:0000945	74.14	gold quality
heart	UBERON:0000948	73.87	gold quality
gastrocnemius	UBERON:0001388	73.82	gold quality
left ovary	UBERON:0002119	73.59	gold quality
omental fat pad	UBERON:0010414	73.48	gold quality
adipose tissue	UBERON:0001013	73.45	gold quality
ovary	UBERON:0000992	73.23	gold quality
left adrenal gland	UBERON:0001234	72.35	gold quality
caudate nucleus	UBERON:0001873	72.16	gold quality
left adrenal gland cortex	UBERON:0035825	72.13	gold quality
right adrenal gland	UBERON:0001233	72.07	gold quality
monocyte	CL:0000576	71.81	gold quality
body of pancreas	UBERON:0001150	71.52	gold quality
heart left ventricle	UBERON:0002084	71.17	gold quality
colon	UBERON:0001155	71.01	gold quality
body of stomach	UBERON:0001161	70.93	gold quality
intestine	UBERON:0000160	70.63	gold quality
transverse colon	UBERON:0001157	70.19	gold quality
right atrium auricular region	UBERON:0006631	69.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.39

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Although fibronectin was induced by miR-377, it was not a direct target of miR-377. overexpression of miR-377 in diabetic nephropathy indirectly leads to increased fibronectin protein production. (PMID:18716028)
• the combination of miR-377 and miR-217 help regulate HO-1 protein expression in the presence of hemin (PMID:21106538)
• Mir-377, mapped to the 14q32.31 locus, regulates proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. (PMID:24166498)
• psiepsilonRACK induced upregulation of hsa-miR-377 expression, coupled to decreases in ADAMTS5 and cleaved aggrecan (PMID:24312401)
• Low expression of miR-377 is associated with glioblastoma. (PMID:24951112)
• MiR-377 and let-7a are implicated in regulation of endogenous cell growth and miR-145 in the placental response to maternal stimulation. (PMID:25077964)
• Our data suggest that miR-377 can suppress proliferation in MG-63 cells in part by targeting CDK6. (PMID:25577249)
• As miR-377 was found to be differentially expressed in clear cell renal carcinoma, and in light of the apparent central role of ETS1 in tumor development, these results indicate that miR-377 could be useful for diagnostics, prognostics and therapeutics. (PMID:25776481)
• MiR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells. (PMID:25889255)
• miR-377 downregulated p53, PTEN and TIMP1 expression by directly targeting the 3’-untranslated region of these target genes. Collectively, miR-377 potentially served as a new molecular predictive biomarker of GC tumorigenesis and prognosis (PMID:25998046)
• Suggest that miR-377 plays an important role in the development of NSCLC by regulating AEG-1 expression. (PMID:26823698)
• Downregulation of miR-377 may contribute to the upregulation of IRX3 in HCC. (PMID:27222047)
• NEAT1 modulated the expression of E2F3 and MiR377 and promoted non small cell lung cancer progression. (PMID:27351135)
• stable ectopic miR-377 expression in pancreatic cancer cell lines suppressed Pim-3 expression, leading to the attenuation of Bad phosphorylation level at its Ser(112) and promoting cell apoptosis. (PMID:27638830)
• miR-377 was markedly downregulated in HCC cell lines and primary human HCC tissues. The decreased expression of miR-377 contributes to the upregulation of Bcl-xL expression by targeting its 3’-untranslated region (3’-UTR). (PMID:28081730)
• HDAC9 is a target of miR-377 in oral squamous cell carcinoma. (PMID:28267394)
• Our results highlight a novel role for miR-377-DNMT1-p53 axis in HSF senescence. These findings shed new light on the mechanisms of skin aging and identify future opportunities for its therapeutic prevention (PMID:28277545)
• miR-377 plays a functional and significant role in suppressing tumor initiation and progression, and may represent a promising non-invasive diagnostic and prognostic biomarker and therapeutic strategy for patients with Esophageal squamous cell carcinoma. (PMID:28288140)
• miR-377 through targeting DNMT1 could reduce DNA methylation of some tumor suppressor genes and restore their expression in pancreatic cancer cells. (PMID:28758420)
• Study found that miR-377 was upregulated in colorectal cancer (CRC) tissues and promoted tumorigenesis by accelerating the G1 -S phase transition, promoting cell proliferation and epithelial-mesenchymal transition while repressing apoptosis in CRC cells. These results suggest that miR-377 functions as an oncogene and promotes carcinogenesis via upregulating GSK-3beta expression and activating NF-kappaB pathway in CRC c… (PMID:28857252)
• Study shows that SESN1 mRNA, UHRF1BP11 mRNA and miRNA-377-3p levels are prognostically relevant in human papillomavirus-negative head and neck squamous cell carcinoma patients. (PMID:28886272)
• Urinary miR-377 and miR-216a can be considered early biomarkers of nephropathy in pediatric type 1 diabetes. Their correlation with carotid intimal thickness provides insights on the subclinical atherosclerotic process that occurs in diabetic nephropathy. (PMID:29175120)
• Overexpression of miR-377 inhibited cell growth, migration and invasion, while downregulation miR-377 obviously promoted cell growth and metastasis. Vascular endothelial growth factor A (VEGFA) was confirmed as a direct target of miR-377 and reversed the influence of mir-377 over-expression. (PMID:29228421)
• Results suggested that miR377 is a significant negative regulator of CUL4A that controls cancer cell progression in ovarian cancer cell lines. (PMID:29512715)
• miR-377 decreases proliferation and invasion of cervical cancer cells by directly targeting ZEB2. (PMID:29523224)
• CASP1 was predicted as a downstream target of miR-377 Overexpression of miR-377 suppressed the expression of CASP1 in PC9 cells and knockdown of miR-377 increased the CASP1 expression in PC9GR cells. (PMID:29592872)
• MIRN377 regulates the expression level of CDH13 by promoting cell proliferation and inhibiting cell apoptosis in a cell model of Alzheimer’s disease. (PMID:29771432)
• The results suggested that bloodbased miR377 and miR192 may serve as potential biomarkers for early detection of diabetic nephropathy. Further validation studies are required with larger sample sizes. (PMID:29845236)
• These data indicate that miR-377-3p suppressed adipogenesis of human bone marrow mesenchymal stem cells by targeting LIFR, which provides novel insights into the molecular mechanism of miRNA-mediated cellular differentiation. (PMID:29959592)
• Collagen regulates the ability of endothelial progenitor cells to protect hypoxic myocardium through a mechanism involving miR-377/VE-PTP axis. (PMID:30044046)
• LASP1 activates the PI3K/AKT signaling pathway and is downregulated by miR-377-3p during glioma progression. (PMID:30372896)
• These results illuminated that the novel Linc00339/miR-377-3p/HOXC6 axis played a critical role in triple-negative breast cancer (TNBC) progression and might be a promising therapeutic target for TNBC treatment. (PMID:30618083)
• Down-regulation of miR-377 could partially suppress high glucose and hypoxia-induced angiogenic functions, restrain pro-inflammatory cytokines release, and its mechanism may though inhibition of NF-kappaB pathway by direct up-regulation of target gene SIRT1 expression. (PMID:30706373)
• miR-377 downregulated the target gene RANKL, resulting in PIO inhibition. MiR-377 relieved PIO by negatively regulating RANKL. (PMID:30958621)
• miR-377-3p inhibited growth and invasion of ovarian cancer cells by targeting JAG1. (PMID:31041680)
• miR-377 may promote osteosarcoma cell apoptosis through inactivation of the HAT1-mediated Wnt signaling pathway. (PMID:31152456)
• This study revealed that circVAPA contributes to Hepatocellular carcinoma (HCC) cell proliferation through sponging miR-377-3p and thereby disinhibiting prosaposin (PSAP), shedding light on a new insight into HCC initiation and progression (PMID:31368365)
• Low miR377 expression is associated with non-small cell lung cancer. (PMID:31479715)
• SP1-mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR-377 to facilitate prostate cancer progression through regulation of ZIC5. (PMID:31608997)
• CircZFR serves as a prognostic marker to promote bladder cancer progression by regulating miR-377/ZEB2 signaling. (PMID:31746333)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir377	ENSMUSG00000065438

Paralogs (16): MIR494 (ENSG00000194717), MIR381 (ENSG00000199020), MIR369 (ENSG00000199025), MIR323A (ENSG00000199069), MIR410 (ENSG00000199092), MIR409 (ENSG00000199107), MIR539 (ENSG00000202560), MIR487A (ENSG00000207742), MIR487B (ENSG00000207754), MIR656 (ENSG00000207959), MIR496 (ENSG00000207961), MIR154 (ENSG00000207978), MIR323B (ENSG00000208004), MIR1185-1 (ENSG00000221525), MIR1185-2 (ENSG00000221614), MIR382 (ENSG00000283170)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.